1. In Vivo
  2. >>Deal-Making

What Do They Want? Securing The Big Pharma Deal

 
• By Andrew Warmington

Partnering has changed in many ways in the last 18 months. Financial markets have all but closed to start-ups and investors are consolidating asset bases in the expectation of relatively high inflation continuing for the next few years.

LSX World Congress 2023
• Source: LSX World Congress 2023

Most of the breakthrough science in pharma continues to come from emerging biotechs, while the size, scale, expertise and connections of big pharma are still essential. How strategies are evolving in this situation was the subject of ‘Early-Stage Pharma Partnering – Building a Strategy For Success’, a big pharma panel at the LSX World Congress in London on 4 May.

Key Takeaway

Big pharma business development players discuss the ongoing global financial challenges and provide ‘how-to’ information for SMEs on making a strong pitch to secure a deal.

Biotechs are making more – and sometimes desperate – approaches to big pharma in the absence of alternatives. Some clinical programs, noted Zaki Salanti, head of search & evaluation (S&E)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo